Epidermal growth factor receptor (478--488)

Epidermal growth factor receptor (478--488) is a synthetic peptide fragment derived from the intracellular domain of the human EGFR protein, corresponding specifically to amino acid residues 478 through 488. As a segment of a key receptor tyrosine kinase involved in cellular signaling, this peptide represents a crucial molecular tool for dissecting EGFR-mediated pathways. Its sequence encompasses regions implicated in protein-protein interactions and regulatory modifications, making it highly relevant for studies focused on signal transduction, phosphorylation events, and receptor function. Researchers utilize this peptide to probe fundamental mechanisms underlying cell growth, differentiation, and oncogenic transformation, given EGFR's central role in these processes.

Peptide mapping: In proteomic and biochemical research, the 478-488 fragment of EGFR serves as a valuable standard for peptide mapping and sequence verification. By providing a defined sequence, it enables precise identification of EGFR-derived peptides in complex mixtures during mass spectrometry-based analyses. This application is particularly important for validating the presence and integrity of EGFR in cell lysates or tissue extracts, supporting studies in receptor expression profiling and post-translational modification mapping.

Kinase substrate studies: The EGFR (478-488) peptide is frequently employed as a model substrate in kinase assays to investigate phosphorylation dynamics. Its sequence contains tyrosine residues that can be targeted by EGFR itself or by other kinases, allowing researchers to monitor phosphorylation efficiency, substrate specificity, and inhibitor effects in vitro. This approach is instrumental in elucidating the biochemical basis of EGFR signaling cascades and in screening for potential modulators of kinase activity.

Antibody validation: This peptide fragment is utilized in immunological assays for the validation and characterization of anti-EGFR antibodies. By serving as a defined antigenic epitope, it enables specificity assessment in ELISA, Western blotting, and immunoprecipitation experiments. Such applications are critical for confirming antibody selectivity and for optimizing reagents used in basic research, diagnostics, and high-throughput screening platforms.

Protein-protein interaction studies: The segment corresponding to amino acids 478-488 of EGFR is implicated in mediating interactions with intracellular signaling partners. Synthetic versions of this peptide are used in binding assays, pull-down experiments, and structural analyses to elucidate the molecular determinants of EGFR's interactions with adaptor proteins, phosphatases, or other regulatory molecules. Insights gained from these studies contribute to a deeper understanding of receptor signaling networks and their dysregulation in disease contexts.

Peptide-based inhibitor design: The defined structure of the EGFR (478-488) fragment provides a foundation for the rational design and testing of peptide-based inhibitors or mimetics. Researchers leverage this sequence to develop molecules that can competitively interfere with natural protein-protein interactions involving the EGFR intracellular domain. Such investigations support the discovery of novel modulators of EGFR function and facilitate the exploration of targeted approaches in signal transduction research.

1. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes

2. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats

3. An Isolated TCR αβ Restricted by HLA-A* 02: 01/CT37 Peptide Redirecting CD8+ T Cells to Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines

4. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy

5. Immune responses to homocitrulline-and citrulline-containing peptides in rheumatoid arthritis